Exec Edge
March Biosciences Designates Dr. Gurpreet Ratra as Chief Business Officer
📈
AI Sentiment
Highly Positive
8/10
- Home
- ADVM
as of 12-05-2025 3:43pm EST
$4.27
+$0.09
+2.28%
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
Chart Type:
Time Range:
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 94.6M | IPO Year: | 2014 |
| Target Price: | $11.60 | AVG Volume (30 days): | 461.9K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.78 - $6.12 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | -72.22% |
| Revenue Growth (this year): | 1192% | Revenue Growth (next year): | -98.03% |
AI-Powered ADVM Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 77.33%
77.33%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Adverum Biotechnologies Inc. (ADVM)
Leonard Braden Michael
Sell
10% Owner
ADVM Dec 3, 2025
Avg Cost/Share
$4.17
Shares
222,925
Total Value
$929,597.25
Owned After
2,428,640
SEC Form 4
Leonard Braden Michael
Sell
10% Owner
ADVM Dec 2, 2025
Avg Cost/Share
$4.20
Shares
51,961
Total Value
$218,236.20
Owned After
2,428,640
SEC Form 4
Leonard Braden Michael
Sell
10% Owner
ADVM Dec 1, 2025
Avg Cost/Share
$4.20
Shares
300,000
Total Value
$1,260,000.00
Owned After
2,428,640
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | ADVM | 10% Owner | Dec 3, 2025 | Sell | $4.17 | 222,925 | $929,597.25 | 2,428,640 | |
| Leonard Braden Michael | ADVM | 10% Owner | Dec 2, 2025 | Sell | $4.20 | 51,961 | $218,236.20 | 2,428,640 | |
| Leonard Braden Michael | ADVM | 10% Owner | Dec 1, 2025 | Sell | $4.20 | 300,000 | $1,260,000.00 | 2,428,640 |
Latest Adverum Biotechnologies Inc. News
ADVM Breaking Stock News: Dive into ADVM Ticker-Specific Updates for Smart Investing
GlobeNewswire
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly
📊
AI Sentiment
Positive
7/10
Compare ADVM vs Leading Stocks
See how ADVM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ADVM Adverum Biotechnologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.